Alunbrig (brigatinib) now available from Onco360!
ALUNBRIG® is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Dosage and Administration
The recommended dosage for ALUNBRIG is 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.
Dosage Forms and Strengths
For more information, visit Alunbrig.com